Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100
The purpose of the research was to optimize the preparation of duloxetine hydrochloride (duloxetine HCl) delayed release tablets. Duloxetine HCl produces a toxic substance called alpha-naphthol when duloxetine HCl is in contact with gastric fluid. Thus, duloxetine HCl when given orally needed a prot...
Saved in:
| Main Authors: | , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Wiley
2021-01-01
|
| Series: | International Journal of Polymer Science |
| Online Access: | http://dx.doi.org/10.1155/2021/8890503 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832550567937835008 |
|---|---|
| author | M. Yasmin Begum Ali Alqahtani Mohammed Ghazwani Noura Abdullah Alhamood Umme Hani Avanthi Jajala Mohamed Rahamathulla |
| author_facet | M. Yasmin Begum Ali Alqahtani Mohammed Ghazwani Noura Abdullah Alhamood Umme Hani Avanthi Jajala Mohamed Rahamathulla |
| author_sort | M. Yasmin Begum |
| collection | DOAJ |
| description | The purpose of the research was to optimize the preparation of duloxetine hydrochloride (duloxetine HCl) delayed release tablets. Duloxetine HCl produces a toxic substance called alpha-naphthol when duloxetine HCl is in contact with gastric fluid. Thus, duloxetine HCl when given orally needed a protective enteric coating that disable the delivery of duloxetine HCl in gastric fluid while enabling the drug delivery only in small intestine. Four different core tablets were prepared by direct compression technique, and the one which displayed quick disintegration and dissolution was chosen for enteric coating. The compressed tablets were enteric coated by dip coating technique. Since subcoating is required to safeguard the enteric coating, the core tablets were subcoated by using polymer HPMC K15M and then enteric coated with Eudragit L 100. The prepared tablets were assessed for the entire precompression and postcompression characteristics. FTIR study revealed the existence of all prominent peaks signifying its compatibility and authenticity. The in vitro studies showed that enteric-coated tablets were capable of restricting release in acidic media. The formulation F8 was optimised with 5% and 15% increase in weight of seal coat and enteric coat with good dissolution profile. Stability studies revealed that the optimized formulation was intact without any deterioration for 3 months. In conclusion, the optimized formulation could resist the drug release in acidic environment of gastrointestinal region and release the drug at a time once the tablet reaches the intestine. |
| format | Article |
| id | doaj-art-7d9ab22261d245eaa540b598bdafed33 |
| institution | Kabale University |
| issn | 1687-9422 1687-9430 |
| language | English |
| publishDate | 2021-01-01 |
| publisher | Wiley |
| record_format | Article |
| series | International Journal of Polymer Science |
| spelling | doaj-art-7d9ab22261d245eaa540b598bdafed332025-02-03T06:06:27ZengWileyInternational Journal of Polymer Science1687-94221687-94302021-01-01202110.1155/2021/88905038890503Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100M. Yasmin Begum0Ali Alqahtani1Mohammed Ghazwani2Noura Abdullah Alhamood3Umme Hani4Avanthi Jajala5Mohamed Rahamathulla6Department of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi ArabiaDepartment of Pharmacology, College of Pharmacy, King Khalid University, Abha, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi ArabiaDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi ArabiaDepartment of Pharmaceutics, Malla Reddy College of Pharmacy (Affiliated to Osmania University), Maisammaguda, Dhulapally, Secunderabad 500100, IndiaDepartment of Pharmaceutics, College of Pharmacy, King Khalid University, Abha, Saudi ArabiaThe purpose of the research was to optimize the preparation of duloxetine hydrochloride (duloxetine HCl) delayed release tablets. Duloxetine HCl produces a toxic substance called alpha-naphthol when duloxetine HCl is in contact with gastric fluid. Thus, duloxetine HCl when given orally needed a protective enteric coating that disable the delivery of duloxetine HCl in gastric fluid while enabling the drug delivery only in small intestine. Four different core tablets were prepared by direct compression technique, and the one which displayed quick disintegration and dissolution was chosen for enteric coating. The compressed tablets were enteric coated by dip coating technique. Since subcoating is required to safeguard the enteric coating, the core tablets were subcoated by using polymer HPMC K15M and then enteric coated with Eudragit L 100. The prepared tablets were assessed for the entire precompression and postcompression characteristics. FTIR study revealed the existence of all prominent peaks signifying its compatibility and authenticity. The in vitro studies showed that enteric-coated tablets were capable of restricting release in acidic media. The formulation F8 was optimised with 5% and 15% increase in weight of seal coat and enteric coat with good dissolution profile. Stability studies revealed that the optimized formulation was intact without any deterioration for 3 months. In conclusion, the optimized formulation could resist the drug release in acidic environment of gastrointestinal region and release the drug at a time once the tablet reaches the intestine.http://dx.doi.org/10.1155/2021/8890503 |
| spellingShingle | M. Yasmin Begum Ali Alqahtani Mohammed Ghazwani Noura Abdullah Alhamood Umme Hani Avanthi Jajala Mohamed Rahamathulla Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100 International Journal of Polymer Science |
| title | Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100 |
| title_full | Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100 |
| title_fullStr | Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100 |
| title_full_unstemmed | Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100 |
| title_short | Development of Duloxetine Hydrochloride Tablets for Delayed and Complete Release Using Eudragit L 100 |
| title_sort | development of duloxetine hydrochloride tablets for delayed and complete release using eudragit l 100 |
| url | http://dx.doi.org/10.1155/2021/8890503 |
| work_keys_str_mv | AT myasminbegum developmentofduloxetinehydrochloridetabletsfordelayedandcompletereleaseusingeudragitl100 AT alialqahtani developmentofduloxetinehydrochloridetabletsfordelayedandcompletereleaseusingeudragitl100 AT mohammedghazwani developmentofduloxetinehydrochloridetabletsfordelayedandcompletereleaseusingeudragitl100 AT nouraabdullahalhamood developmentofduloxetinehydrochloridetabletsfordelayedandcompletereleaseusingeudragitl100 AT ummehani developmentofduloxetinehydrochloridetabletsfordelayedandcompletereleaseusingeudragitl100 AT avanthijajala developmentofduloxetinehydrochloridetabletsfordelayedandcompletereleaseusingeudragitl100 AT mohamedrahamathulla developmentofduloxetinehydrochloridetabletsfordelayedandcompletereleaseusingeudragitl100 |